Table 1 Baseline demographic and clinical characteristics
From: Severe COVID anxiety among adults in the United Kingdom: cohort study and nested feasibility trial
Variable | Category | Completers (N = 204) | Non-completers (N = 81) | ||
|---|---|---|---|---|---|
n | Summary | n | Summary | ||
Age | Age | 201 | 41.2 [28.5, 53.1] | 81 | 35.3 [27.5, 52.1] |
Gender | Female | 201 | 162 (80.6%) | 81 | 64 (79.0%) |
Male | Â | 39 (19.4%) | Â | 17 (21.0%) | |
Ethnicity | White | 198 | 162 (81.8%) | 78 | 61 (78.2%) |
Asian | Â | 21 (10.6%) | Â | 5 (6.4%) | |
Black | Â | 9 (4.6%) | Â | 3 (3.9%) | |
Mixed | Â | 4 (2.0%) | Â | 7 (9.0%) | |
Other | Â | 2 (1.0%) | Â | 2 (2.6%) | |
In employment | No | 201 | 118 (58.7%) | 80 | 35 (43.7%) |
Yes | Â | 83 (41.3%) | Â | 45 (56.3%) | |
Lives alone | No | 201 | 166 (82.6%) | 80 | 64 (80.0%) |
Yes | Â | 35 (17.4%) | Â | 16 (20.0%) | |
Lives with a | No | 198 | 128 (64.6%) | 78 | 38 (47.7%) |
vulnerable person | Yes | Â | 70 (35.4%) | Â | 40 (51.3%) |
Medical | No | 200 | 72 (36.0%) | 80 | 35 (43.7%) |
condition | Yes | Â | 128 (64.0%) | Â | 45 (56.3%) |
At risk | No | 200 | 144 (72.0%) | 80 | 66 (82.5%) |
condition | Yes | Â | 56 (28.0%) | Â | 14 (17.5%) |
Drug use in the | No | 193 | 178 (92.2%) | 71 | 62 (87.3%) |
last year | Yes | Â | 15 (7.8%) | Â | 9 (12.7%) |
CAS | - | 204 | 12.2 ± 2.7 | 81 | 12.8 ± 3.6 |
WSAS | - | 195 | 22.0 ± 7.4 | 72 | 19.3 ± 8.1 |
GAD-7 | - | 197 | 16 [13, 19] | 77 | 16 [12, 19] |
sHAI | - | 196 | 23.3 ± 6.7 | 73 | 23.0 ± 8.3 |
PHQ-9 | - | 196 | 15.5 ± 5.5 | 72 | 15.8 ± 5.6 |
OCI-R | - | 193 | 29.9 ± 14.8 | 71 | 31.7 ± 16.6 |
SAPAS | - | 192 | 4.2 ± 1.8 | 71 | 4.0 ± 1.9 |
DPQ | - | 193 | 10.6 ± 4.1 | 71 | 11.7 ± 4.1 |
AUDIT-C | - | 193 | 2 [0, 4] | 71 | 3 [0, 6] |